SEC Form 4 · accession 0001144204-18-019667
CASI Pharmaceuticals, Inc. · CASI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Huang
Director
Period of report
Apr 4, 2018
Accepted (ET)
Apr 6, 2018 · 5:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000895051
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 4, 2018 | J | 416,666 | $0.00 | D | 0 | I | See footnote |
| Common Stock | Apr 4, 2018 | J | 191 | $0.00 | A | 191 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Like-kind distribution of shares by KPCB China Fund II, LP ("KPCB") to its limited partners. The general partner of KPCB is KPCB China Associates II, L.P. ("Associates "). The general partner of Associates is KPCB China Holdings II, Ltd., of which the Reporting Person is a director. The Reporting Person received 191 shares as a result of his interest in KPCB.